Skip to main content
SpringerLink
Log in

Lack of Pharmacokinetic Interaction Between Cimetidine and Tirilazad Mesylate

  • Note
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. J. M. Braughler, E. D. Hall, J. Jacobsen, J. M. McCall, and E. D. Means. The 21-aminosteroids: Potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 14:143–152 (1989).

    Google Scholar 

  2. J. C. Fleishaker, G. R. Peters, and K. S. Cathcart. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger. I. Single dose administration. J. Clin. Pharmacol. 33:175–181 (1993).

    Google Scholar 

  3. L. K. Hulst, J. C. Fleishaker, G. R. Peters, J. D. Harry, and D. M. Wright. Pharmacokinetics of tirilazad mesylate following IV administration of 1.5 mg/kg and 3.0 mg/kg to healthy young and elderly subjects. Pharm. Res. 9(Suppl):S307 (1992).

    Google Scholar 

  4. J. C. Fleishaker, L. K. Hulst, and G. R. Peters. Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. J. Clin. Pharmacol. (in press).

  5. J. C. Fleishaker, G. R. Peters, K. S. Cathcart, and R. C. Steenwyk. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger. II. Multiple dose administration. J. Clin. Pharmacol. 33:182–190 (1993).

    Google Scholar 

  6. R. P. Stryd, M. A. Wynalda, M. T. Verburg, U. M. Rykert, J. A. Shah, J. C. Fleishaker, and D. G. Kaiser. Comparison of intact drug vs. total drug-related materials in plasma following single-dose IV administration of [14C]tirilazad mesylate to rabbit, dog, monkey and human. Pharm. Res. 9(Suppl):S312 (1992).

    Google Scholar 

  7. D. J. Waxman. Interactions of hepatic cytochromes P-450 with steroid hormones: regioselectivity and stereospecificity of steroid metabolism and hormonal regulation of rat P-450 enzyme expression. Biochem. Pharmacol. 37:71–84 (1988).

    Google Scholar 

  8. S. R. Smith and M. J. Kendall. Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions. Clin. Pharmacokinet. 15:44–56 (1988).

    Google Scholar 

  9. R. G. Knodell, D. G. Browne, G. P. Gwozdz, W. R. Brian, and F. P. Guengerich. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 101:1680–1691 (1991).

    Google Scholar 

  10. D. M. Grasela, M. L. Rocci, H. H. Rottmensch, and P. H. Vlasses. Lack of effect of multiple doses of cimetidine on estimated hepatic blood flow. Biopharm. Drug Disp. 8:63–72 (1987).

    Google Scholar 

  11. N. K. Hopkins, M. K. Larson, and G. D. Hanson. Determination of tirilazad mesylate (U-74,006F) and its metabolite (M-1) in human plasma using high performance liquid chromatography (submitted for publication).

  12. M. G. Kunitani, D. A. Johnson, R. A. Upton, and S. Riegelman. Convenient and sensitive high performance liquid chromatography assay for cimetidine in plasma. J. Chromatogr. 224:156–161 (1981).

    Google Scholar 

  13. M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed., Marcell Dekker, New York, 1982.

    Google Scholar 

  14. D. M. Grasela, M. L. Rocci, and P. H. Vlasses. Experimental impact of assay-dependent differences in plasma indocyanine green concentration determinations. J. Pharmacokinet. Biopharm. 15:601–613 (1987).

    Google Scholar 

  15. F. P. Guengerich. Human cytochrome-P-450 enzymes. Life Sci. 50:1471–1478 (1992).

    Google Scholar 

  16. B. K. Park and N. R. Kitteringham. Assessment of enzyme induction and enzyme inhibition in humans: Toxicological implications. Xenobiotica 20:1171–1185 (1990).

    Google Scholar 

  17. G. Bodemar, B. Norlander, and A. Walan. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin. Pharmacokinet. 6:306–315 (1981).

    Google Scholar 

  18. J. Webster, H. E. Barber, G. M. Hawksworth, T. A. Jeffers, J. Petersen, J. C. Petrie, P. W. Brunt, N. A. G. Mowat, and R. Griffiths. Cimetidine—a clinical and pharmacokinetic study. Br. J. Clin. Pharmacol. 11:333–338 (1981).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacokinetics and Clinical Research Units, The Upjohn Company, Kalamazoo, Michigan, 49007

    Joseph C. Fleishaker, Laura K. Hulst & Gary R. Peters

Authors
  1. Joseph C. Fleishaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura K. Hulst
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary R. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleishaker, J.C., Hulst, L.K. & Peters, G.R. Lack of Pharmacokinetic Interaction Between Cimetidine and Tirilazad Mesylate. Pharm Res 11, 341–344 (1994). https://doi.org/10.1023/A:1018988331700

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018988331700

Search

Navigation